Nanobiotix Prices Oversubscribed $98.6M Global Offering, Extends Cash Runway to 2029

summarizeSummary

Nanobiotix announced the pricing of its oversubscribed global offering, raising $98.6 million to extend its cash runway into 2029, with support from existing major shareholders.

check_boxKey Events

• Global Offering Priced

  Nanobiotix priced its global follow-on offering, consisting of American Depositary Shares (ADSs) at $38.98 per ADS and Ordinary Shares/Pre-Funded Warrants (PFWs) at €33.60/€33.57 respectively.

• Significant Capital Raise

  The offering is expected to generate approximately $98.6 million (€85.0 million) in gross proceeds, a material increase from the previously announced target of $87 million.

• Oversubscribed with Investor Support

  The offering was oversubscribed and supported by existing shareholders, including Qatar Holding LLC and Invus, signaling strong demand and confidence.

• Extended Cash Runway

  The net proceeds, combined with existing cash, are projected to fund the company's working capital requirements and operations into 2029.

auto_awesomeAnalysis

Nanobiotix has successfully priced its global follow-on offering, raising approximately $98.6 million. This capital infusion is critical for a late-clinical stage biotechnology company, as it significantly extends the company's cash runway into 2029. The offering was oversubscribed and saw participation from existing major shareholders, indicating strong investor confidence despite the dilutive nature of the transaction and the offering price being at a discount to the recent volume-weighted average price. The funds will primarily support the advancement of its Nanoprimer and other platforms, as well as general corporate purposes.